Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW))) ("Estrella", "Estrella Immunopharma", or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the Company dosed the first patient in its Phase I/II clinical trial (STARLIGHT-1) for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL). Ms. Zhang's appointment increases the size of Estrella's Board from five to six dire

Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin's Lymphomas (NHL). The second cohort will evaluate EB103 at a higher dose level following a review of safety data from the first dose cohort. As previously announced, no dose-limiting toxicities (DLTs) or treatment-related serious adverse e

Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that CB Capital Partners has initiated coverage on the Company with a Buy rating and a price target of $14.00. "We appreciate CB Capital's detailed evaluation of our proprietary ARTEMIS® T-cell platform and the progress we have made with EB103," said Dr. Cheng Liu, President and Chief Executive Officer of Estrella. "Their report highlights the unique attributes of our approach to T-cell therapy and underscores the potential for our pipeline to deliver transform

Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of safety and efficacy data, the Data and Safety Monitoring Board (DSMB) has approved the initiation of the second dose cohort, which will administer 5 million receptor-positive T cells per kilogram of body weight of EB103 CD19-Redirected ARTEMIS® T-cell therapy. The first dose cohort included patients with relapsed/refractory B-cell non-Ho

Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that D. Boral Capital LLC ("D. Boral Capital"), a leading investment bank, has initiated coverage on the Company, assigning a Buy rating to Estrella and established a 12-month price target of $16.00. Valuation Highlights D. Boral Capital's analysis focuses on the development of EB103 in B-cell Non-Hodgkin's Lymphoma, emphasizing Estrella's ARTEMIS® T-cell engineering platform that utilizes cellular mechanisms which closely resemble those of endogenous

Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW))) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response (CR) one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS® T Cells. In a clinical trial, a complete response means that no detectable signs of disease or cancer remain after treatment. The patient, diagnosed with follicular lymphoma grade 3A with high-risk 3B symptoms, was enrolled in the STARLIGHT-1 trial at UC Davis Compreh

Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW))) ("Estrella", "Estrella Immunopharma", or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the Company dosed the first patient in its Phase I/II clinical trial (STARLIGHT-1) for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL). Ms. Zhang's appointment increases the size of Estrella's Board from five to six dire

8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)

10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)

8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)

10-KT - Estrella Immunopharma, Inc. (0001844417) (Filer)

8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)

S-8 - Estrella Immunopharma, Inc. (0001844417) (Filer)

EFFECT - Estrella Immunopharma, Inc. (0001844417) (Filer)

424B3 - Estrella Immunopharma, Inc. (0001844417) (Filer)

8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)

S-3 - Estrella Immunopharma, Inc. (0001844417) (Filer)

4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)